Relapsing Remitting Multiple Sclerosis News and Research

RSS

Taking estriol along with conventional medications helps RRMS patients avoid relapses

Taking the pregnancy hormone estriol along with their conventional medications helped patients with relapsing-remitting multiple sclerosis (RRMS) avoid relapses, according to results of a Phase II randomized, placebo-controlled study led by UCLA researchers.

1 Dec 2015

GATE opens for generic equivalent to glatiramer acetate in MS

Findings from the GATE study have shown equivalent efficacy and tolerability for a generic version of glatiramer acetate to that of the original brand version in the treatment of relapsing–remitting multiple sclerosis.

15 Oct 2015

Daclizumab HYP superior to interferon in relapsing–remitting MS

The DECIDE study shows that 4-weekly daclizumab high-yield process reduces disease activity in patients with relapsing–remitting multiple sclerosis more effectively than weekly interferon beta-1a, albeit at the cost of more adverse effects.

8 Oct 2015

Interim data from long-term extension Tecfidera® (dimethyl fumarate) study

Biogen (NASDAQ: BIIB) will, this week, present data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, demonstrating the efficacy and safety of TECFIDERA® (dimethyl fumarate) across a broad range of people with relapsing-remitting multiple sclerosis (RRMS).

7 Oct 2015

Quitting smoking may delay secondary progressive MS onset

Patients who are smokers when diagnosed with relapsing–remitting multiple sclerosis may be able to delay the time to onset of progressive disease by quitting smoking, a study suggests.

1 Oct 2015

Mental visual imagery training may improve AM/EFT functioning in RR-MS patients

Patients with relapsing-remitting multiple sclerosis (RR-MS), the most common form of the disease, often have deficits in two neuropsychological functions, autobiographical memory (AM) and episodic future thinking (EFT), which impact quality of life.

26 Aug 2015

Shorter washout period during transition from natalizumab supported

A prematurely halted trial provides support for a relatively short washout period when transitioning patients with relapsing–remitting multiple sclerosis from natalizumab to fingolimod.

5 Jun 2015

New longer-term data on Genzyme's relapsing MS treatments to be presented at AAN 2015

Genzyme, a Sanofi company, announced today that new longer-term data on its relapsing multiple sclerosis treatments, Aubagio (teriflunomide) and Lemtrada (alemtuzumab), will be featured during the 67th annual meeting of the American Academy of Neurology being held in Washington, D.C. April 18-25.

15 Apr 2015

University of Cambridge's Alastair Compston wins 2015 John Dystel Prize for MS Research

The American Academy of Neurology and the National Multiple Sclerosis Society are awarding the 2015 John Dystel Prize for MS Research to Alastair Compston, MBBS, PhD, Professor of Neurology at the University of Cambridge.

11 Mar 2015

Promising results for stem cell therapy in MS

Preliminary findings suggest that nonmyeloablative haematopoietic stem cell transplantation may arrest, or even reverse, the progress of disease among patients with relapsing–remitting multiple sclerosis.

28 Jan 2015

Study: Stem cell transplantation improves quality of life in patients with relapsing-remitting MS

Results from a preliminary study indicate that among patients with relapsing-remitting multiple sclerosis (MS), treatment with nonmyeloablative hematopoietic stem cell transplantation (low intensity stem cell transplantation) was associated with improvement in measures of disability and quality of life, according to a study in the January 20 issue of JAMA.

21 Jan 2015

Phase IIa clinical trial data of ATL1102 in MS patients published in journal Neurology

Antisense Therapeutics is pleased to report the publication of previously generated Phase IIa clinical trial data on ATL1102 in the medical journal Neurology.

22 Sep 2014

Dimethyl fumarate offers no added benefits for adults with RRMS

Dimethyl fumarate has been approved since January 2014 for adults with relapsing remitting multiple sclerosis.

8 Aug 2014

Biogen Idec receives marketing authorization from EC for multiple sclerosis drug

Today Biogen Idec announced that the European Commission (EC) has granted marketing authorization for PLEGRIDY (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS).

25 Jul 2014

Study: People with mobility impairments under age 65 have higher rates of smoking

Researchers from The Miriam Hospital have found that people with mobility impairments under age 65 have significantly higher rates of smoking than those without mobility impairments.

13 Jul 2014

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY), announced today that Argentina's National Administration of Drugs, Food and Medical Technology (ANMAT) has approved LemtradaTM (alemtuzumab) for adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.

30 Jun 2014

Merck Serono launches web-based software system for MS patients receiving Rebif treatment

A new web and app-based software solution, launched in the UK today on World MS Day, will allow physicians and nurses to monitor treatment of patients taking MS disease-modifying treatment Rebif by collecting injection history through the new RebiSmart 2.0 electronic autoinjector.

28 May 2014

Pharmaceutical Executive Magazine names COPAXONE therapy as 2014 "Brand of The Year"

Teva Pharmaceutical Industries Ltd., today announced that COPAXONE (glatiramer acetate injection), the #1 global therapy for relapsing multiple sclerosis, has been named the 2014 "Brand of The Year" by Pharmaceutical Executive Magazine, a leading print and online publication for the biopharmaceutical industry.

9 May 2014

New two-year data from Biogen Idec’s Phase 3 trial for peginterferon beta-1a presented at AAN annual meeting

New two-year data from the Phase 3 ADVANCE clinical trial for peginterferon beta-1a in adults with relapsing forms of multiple sclerosis (RMS) has been presented at the 66th American Academy of Neurology (AAN) annual meeting.

5 May 2014

New data from EMD Serono's multiple sclerosis portfolio to be presented at the 66th AAN Annual Meeting

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that new data from the company's multiple sclerosis (MS) portfolio will be presented at the American Academy of Neurology's 66th Annual Meeting, taking place from April 26 – May 3, in Philadelphia, PA.

26 Apr 2014